These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 33866520)

  • 1. Prognostic factors in advanced pancreatic ductal adenocarcinoma patients-receiving second-line treatment: a single institution experience.
    Gutierrez-Sainz L; Viñal D; Villamayor J; Martinez-Perez D; Garcia-Cuesta JA; Ghanem I; Custodio A; Feliu J
    Clin Transl Oncol; 2021 Sep; 23(9):1838-1846. PubMed ID: 33866520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of neutrophil to lymphocyte ratio in patients with advanced pancreatic ductal adenocarcinoma treated with systemic chemotherapy.
    Kitsugi K; Kawata K; Noritake H; Chida T; Ohta K; Ito J; Takatori S; Yamashita M; Hanaoka T; Umemura M; Matsumoto M; Morita Y; Takeda M; Furuhashi S; Kitajima R; Muraki R; Ida S; Matsumoto A; Suda T
    Ann Med; 2024 Dec; 56(1):2398725. PubMed ID: 39221763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. First-line liposomal irinotecan with oxaliplatin, 5-fluorouracil and leucovorin (NALIRIFOX) in pancreatic ductal adenocarcinoma: A phase I/II study.
    Wainberg ZA; Bekaii-Saab T; Boland PM; Dayyani F; Macarulla T; Mody K; Belanger B; Maxwell F; Moore Y; Thiagalingam A; Wang T; Zhang B; Dean A
    Eur J Cancer; 2021 Jul; 151():14-24. PubMed ID: 33957442
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of second-line chemotherapies for ductal pancreatic adenocarcinoma in a German single-center cohort.
    Maier-Stocker C; Bitzer M; Malek NP; Plentz RR
    Scand J Gastroenterol; 2014 Dec; 49(12):1480-5. PubMed ID: 25390691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response and Survival Associated With First-line FOLFIRINOX vs Gemcitabine and nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma.
    Perri G; Prakash L; Qiao W; Varadhachary GR; Wolff R; Fogelman D; Overman M; Pant S; Javle M; Koay EJ; Herman J; Kim M; Ikoma N; Tzeng CW; Lee JE; Katz MHG
    JAMA Surg; 2020 Sep; 155(9):832-839. PubMed ID: 32667641
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
    Riedl JM; Posch F; Horvath L; Gantschnigg A; Renneberg F; Schwarzenbacher E; Moik F; Barth DA; Rossmann CH; Stotz M; Schaberl-Moser R; Pichler M; Stöger H; Greil R; Djanani A; Schlick K; Gerger A
    Eur J Cancer; 2021 Jul; 151():3-13. PubMed ID: 33951545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
    Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
    BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictors of Resectability and Survival in Patients With Borderline and Locally Advanced Pancreatic Cancer who Underwent Neoadjuvant Treatment With FOLFIRINOX.
    Michelakos T; Pergolini I; Castillo CF; Honselmann KC; Cai L; Deshpande V; Wo JY; Ryan DP; Allen JN; Blaszkowsky LS; Clark JW; Murphy JE; Nipp RD; Parikh A; Qadan M; Warshaw AL; Hong TS; Lillemoe KD; Ferrone CR
    Ann Surg; 2019 Apr; 269(4):733-740. PubMed ID: 29227344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer.
    Chung KH; Ryu JK; Lee BS; Jang DK; Lee SH; Kim YT
    J Gastroenterol Hepatol; 2016 Feb; 31(2):506-12. PubMed ID: 26250642
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FOLFIRINOX as Initial Treatment for Localized Pancreatic Adenocarcinoma: A Retrospective Analysis by the Trans-Atlantic Pancreatic Surgery Consortium.
    Janssen QP; van Dam JL; Doppenberg D; Prakash LR; van Eijck CHJ; Jarnagin WR; O' Reilly EM; Paniccia A; Besselink MG; Katz MHG; Tzeng CD; Wei AC; Zureikat AH; Groot Koerkamp B;
    J Natl Cancer Inst; 2022 May; 114(5):695-703. PubMed ID: 35157075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies.
    Yamamoto KN; Nakamura A; Liu LL; Stein S; Tramontano AC; Kartoun U; Shimizu T; Inoue Y; Asakuma M; Haeno H; Kong CY; Uchiyama K; Gonen M; Hur C; Michor F
    PLoS One; 2019; 14(4):e0215409. PubMed ID: 31026288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of Capecitabine Plus Oxaliplatin Combination Chemotherapy for Advanced Pancreatic Cancer after Failure of First-Line Gemcitabine-Based Therapy.
    Chung KH; Ryu JK; Son JH; Lee JW; Jang DK; Lee SH; Kim YT
    Gut Liver; 2017 Mar; 11(2):298-305. PubMed ID: 27965478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcomes of Second-Line Chemotherapy after Progression on Nab-Paclitaxel Plus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma.
    Lee K; Bang K; Yoo C; Hwang I; Jeong JH; Chang HM; Oh D; Song TJ; Park DH; Lee SS; Lee SK; Kim MH; Park JH; Kim KP; Ryoo BY
    Cancer Res Treat; 2020 Jan; 52(1):254-262. PubMed ID: 31291709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma.
    Vienot A; Beinse G; Louvet C; de Mestier L; Meurisse A; Fein F; Heyd B; Cleau D; d'Engremont C; Dupont-Gossart AC; Lakkis Z; Tournigand C; Bouché O; Rousseau B; Neuzillet C; Bonnetain F; Borg C; Vernerey D
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 28383673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Current Standard and Future Perspectives in First- and Second-Line Treatment of Metastatic Pancreatic Adenocarcinoma.
    Ellenrieder V; König A; Seufferlein T
    Digestion; 2016; 94(1):44-9. PubMed ID: 27438590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-Line Treatment for Advanced Pancreatic Adenocarcinoma: Is There a Role for Gemcitabine?
    Girardi DM; Faria LDBB; Teixeira MC; Costa FP; Hoff PMG; Fernandes GS
    J Gastrointest Cancer; 2019 Dec; 50(4):860-866. PubMed ID: 30175393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
    Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
    Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes of liposomal irinotecan in patients with advanced pancreatic cancer previously treated with conventional irinotecan: A meta-analysis of real-world evidence.
    Gupta A; De Jesus-Acosta A; Le D; Pishvaian M; Zaidi N; Zheng L; Laheru D
    Cancer; 2024 Nov; 130(21):3734-3744. PubMed ID: 38985839
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
    Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of FOLFIRINOX and gemcitabine-nab paclitaxel for metastatic pancreatic cancer in the real world setting.
    Franco F; Camara JC; Martín-Valadés JI; López-Alfonso A; Marrupe D; Gutiérrez-Abad D; Martínez-Amores B; León A; Juez I; Pérez M; Royuela A; Ruiz-Casado A
    Clin Transl Oncol; 2021 Apr; 23(4):812-819. PubMed ID: 32857340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.